🏆 Deal of the Week · CW 19/2021
Huma raised USD 130 million in a Series C financing round; the post-money valuation was not disclosed. The round drew participation from a consortium of strategic and financial investors spanning the pharmaceutical, technology, and consumer goods sectors. Huma was recognised as Venionaire DealMatrix Deal of the Week for KW 19/2021.
Huma — key deal facts
| Company | Huma |
| Founded | 2015 |
| Headquarters | London, United Kingdom |
| Amount raised | USD 130M |
| Valuation | Remains Undisclosed |
| Round | Series C |
| Investors | Bayer (https://www.bayer.com/de/) Hitachi Ventures (https://www.hitachi.com/) Samsung Next (https://www.samsungnext.com/) Sony Innovation Fund by IGV (https://www.sonyinnovationfund.com/portfolio/) Unilever Ventures (https://www.unileverventures.com/) HAT Technology & Innovation Fund by HAT (https://www.hat.it/it/businesses/private-equity/hat-technology-innovation-fund) Business Angel |
| Sectors | Health Care |
Who invested in Huma?
The Series C was backed by Bayer, Hitachi Ventures, Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures, HAT Technology & Innovation Fund by HAT, and at least one undisclosed business angel. The investor mix is notable for its breadth: it combines a major pharmaceutical group, two leading Asian electronics conglomerates, a consumer staples venture arm, and a European deep-tech fund, reflecting Huma's cross-industry positioning at the intersection of clinical care, consumer health, and enterprise technology.
What does Huma do?
Huma is a global healthcare AI company headquartered in London, United Kingdom, founded in 2015 under the original name Medopad before rebranding to Huma in April 2020. The company builds a regulated, disease-agnostic cloud platform that integrates data from hospital systems, patient wearables, and mobile devices to support remote patient monitoring, digital clinical trials, and AI-assisted care management. Its software is deployed across more than 70 countries and serves over 3,000 hospitals and clinics. Huma was founded by Dan Vahdat, who serves as its CEO.
Huma valuation & multiples
No verified revenue or EBITDA figures are publicly available for this financing round, and no multiples analysis has been established for this deal. Once comparable transaction data is available, EV/Sales and EV/EBITDA benchmarks can be assessed against relevant digital health and healthcare technology peers. Readers seeking current sector valuation ranges are invited to explore the Venionaire DealMatrix Health Care multiples pages.
Explore the benchmarks: Series C.
Frequently asked questions
How much did Huma raise in its Series C?
Huma raised USD 130 million in its Series C financing round, recognised by Venionaire DealMatrix in KW 19/2021.
What is Huma's valuation?
Huma's post-money valuation following the Series C remains undisclosed.
Who invested in Huma?
The Series C investors include Bayer, Hitachi Ventures, Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures, HAT Technology & Innovation Fund by HAT, and a business angel.
When was Huma founded and where is it based?
Huma was founded in 2015 and is headquartered in London, United Kingdom.
Source: original announcement — read the full report.